Emergent BioSolutions (EBS) SVP sells 3,000 shares under plan

Rhea-AI Filing Summary

Emergent BioSolutions Inc. reported an insider stock sale by senior vice president Paul Anthony Williams. On July 1, 2026, he executed an open-market sale of 3,000 shares of common stock at a weighted average price of $8.40 per share, with individual sale prices ranging from $8.31 to $8.46. The transaction was made under a pre-arranged trading plan adopted on November 14, 2025 intended to comply with Rule 10b5-1. Following this sale, Williams directly holds 159,098 shares of Emergent BioSolutions common stock.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares ($25,200)

Net Sell 1 txn

Insider Williams Paul Anthony

Role SVP, Products Business

Sold 3,000 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$8.40	$25K

Holdings After Transaction: Common Stock — 159,098 shares (Direct, null)

Footnotes (1)

1. All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 3,000 shares Weighted average sale price: $8.40 per share Sale price range: $8.31–$8.46 per share +3 more

6 metrics

Shares sold 3,000 shares Open-market sale of common stock on July 1, 2026

Weighted average sale price $8.40 per share Common stock sale by SVP Paul Anthony Williams

Sale price range $8.31–$8.46 per share Multiple transactions included in the reported sale

Shares held after transaction 159,098 shares Direct ownership following the July 1, 2026 sale

Gross transaction value $25,200 3,000 shares sold at $8.40 weighted average price

10b5-1 plan adoption date November 14, 2025 Pre-arranged trading plan governing the reported sale

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, common stock

4 terms

Rule 10b5-1(c) regulatory

"plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale","transaction_code_description": "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

common stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 12:57 PM Accepted by SEC EDGAR 07/02/2026 - 12:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Paul Anthony

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Products Business

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S		3,000(1)	D	$8.4(2)	159,098	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Emergent BioSolutions (EBS) disclose?

Emergent BioSolutions disclosed that SVP Paul Anthony Williams sold 3,000 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.40, with prices between $8.31 and $8.46 per share.

Who at Emergent BioSolutions (EBS) sold shares and what is his role?

Senior Vice President, Products Business, Paul Anthony Williams sold the shares. He is an officer of Emergent BioSolutions and remains a substantial shareholder after the transaction, directly holding 159,098 shares of common stock following the reported sale.

How many Emergent BioSolutions (EBS) shares were sold and at what price?

Paul Anthony Williams sold 3,000 shares of Emergent BioSolutions common stock. The weighted average sale price was $8.40 per share, with individual trades executed in a price range from $8.31 to $8.46 during the transaction.

How many Emergent BioSolutions (EBS) shares does the insider hold after the sale?

After the reported sale, Paul Anthony Williams directly holds 159,098 shares of Emergent BioSolutions common stock. This figure reflects his position after disposing of 3,000 shares in the open-market transaction disclosed in the Form 4 filing.

Was the Emergent BioSolutions (EBS) insider sale under a Rule 10b5-1 plan?

Yes. The filing states all transactions were made under a trading plan adopted on November 14, 2025. The plan is intended to comply with Rule 10b5-1(c), indicating the sales were pre-arranged rather than timed at the insider’s discretion.

What does the weighted average price mean in the EBS insider sale?

The weighted average price of $8.40 means multiple trades occurred at different prices between $8.31 and $8.46. The insider commits to provide detailed trade-by-trade pricing information to the company, shareholders, or SEC staff upon request, as noted in the filing.